Dr Sally Baron-Hay

Sally Baron-Hay, MBBS FRACP is a medical oncologist with over 20 years of clinical experience and senior lecturer at the University of Sydney, with clinical appointments at Royal North Shore Hospital in Sydney, North Shore Private Hospital, The Mater Hospital and Genesis Care.

She completed her undergraduate training at the University Western Australia and Sir Charles Gairdner Hospital before travelling to the UK to work in the Breast and Gynaeoncology Units at the Royal Marsden Cancer Centre, South Kensington, London where she developed her interest in translational oncology clinical trials. She completed her medical oncology training at RNSH, St. Leonards, and Royal Prince Alfred Hospital, Camperdown. Her basic research at the Kolling Institute, St Leonards investigated the role of Insulin Like Growth Factors in the pathogenesis and progression of Epithelial Ovarian Cancer. She received a NHMRC Scholarship and won the AACR Young Cancer Investigator award for this research.

Since 2000 she has been a principal investigator on both collaborative and sponsored phase I-III clinical trials in breast and gynaecological malignancies. Many of these have changed the standard of care for women with these malignancies. She sits on the Ovarian Cancer working tumour group within the Australian New Zealand Gynaeoncology Group pivotal to bringing new investigator lead trial concepts into the clinic. She has an interest in developing guidelines for the safe follow up and care for patients both during and following their cancer treatment.

She is a supervisor and mentor for Advanced Medical Oncology Trainees through the Royal Australasian College of Physicians undertaking their training at RNSH and educating medical students in the medical oncology discipline. She sits on the eviQ Medical Oncology Reference Committee for Breast and Gynaeoncology treatment protocols.

Her main interests now focus on the clinical management and improvement in outcomes for women with Breast and Gynaecological malignancies, through the identification of personalised new treatments. The future holds continual improvement in patient care and outcomes and it is this knowledge that keeps her motivated and engaged in the care of her patients.